Neuroendocrine liver metastasis treated by using intraarterial therapy: Volumetric functional imaging biomarkers of early tumor response and survival

Radiology

Volumn 266, Issue 2, 2013, Pages 502-513

  Halappa, Vivek Gowdra ^a   Corona Villalobos, Celia Pamela ^a   Bonekamp, Susanne ^a   Li, Zhen ^a   Reyes, Diane ^a   Cosgrove, David ^b   Pawlik, Timothy M ^a   Diaz, Luis Alberto ^b   Bhagat, Nikhil ^a   Eng, John ^a   Geschwind, Jean François ^a   Kamel, Ihab R ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GADOLINIUM PENTETATE MEGLUMINE; MITOMYCIN;

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DRUG RESPONSE; FEMALE; HUMAN; IMAGE ANALYSIS; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE LIVER METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

CHEMOEMBOLIZATION, THERAPEUTIC; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84873337021     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12120495     Document Type: Article

References (39)

1. Shebani KO, Souba W W, Finkelstein DM, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999;229(6):815-821; discussion 822-823.
2. Norheim I, Oberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors: an analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987;206(2):115-125.
3. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79(4):813-829.
4. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340(11):858-868.
5. Oberg K. Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 2003;3(6):863-877.
6. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005;19(5):753-781.
7. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010;39(6):707-712.
8. Cadiot G, Vuagnat A, Doukhan I, et al. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Néoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology 1999;116(2):286-293.
9. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004;240(5):757-773.
10. Norton JA, Jensen RT. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg Oncol 2003;12(2):145-151.
11. Mayo SC, De Jong MC, Bloomston M, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 2011;18(13):3657-3665.
12. Mayo SC, De Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010;17(12):3129-3136.
13. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27(28):4656- 4663.
14. Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol 2006;17(8):1235-1249; quiz 1250.
15. Oberstein PE, Saif M W. Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
16. JOP 2011;12(4):358-361.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47(1):207-214.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
19. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421-430.
20. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30(1):52-60.
21. Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 2006;17(3):505-512.
22. Kamel IR, Bluemke DA. Magnetic resonance imaging of the liver: assessing response to treatment. Top Magn Reson Imaging 2002;13(3):191-200.
23. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42(5):1208-1236.
24. Liapi E, Geschwind JF, Vossen JA, et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol 2008;190(1):67-73.
25. Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007;18(1 Pt 1):49-56.
26. Halappa VG, Bonekamp S, Corona-Villalobos CP, et al. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology 2012;264(1):285-294.
27. Geschwind JF, Ramsey DE, Cleffken B, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 2003;26(2):111-117.
28. Grady L. Random walks for image segmentation. IEEE Trans Pattern Anal Mach Intell 2006;28(11):1768-1783.
29. Gulsun MA, Weiss CR, Strecker R, Meredith G, Kamel IR. A new tool for volumetric and functional analysis of hepatic tumors monitored with multi-modal MRI [abstr]. In: Proceedings of the Seventeenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2009;2876.
30. Ross BD, Moffat BA, Lawrence TS, et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003;2(6):581-587.
31. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009;250(2):466-473.
32. Riaz A, Lewandowski RJ, Kulik L, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol 2010;33(6):1143-1152.
33. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009;49(4):1185-1193.
34. Assumpcao L, Choti M, Pawlik TM, Gecshwind JF, Kamel IR. Functional MR imaging as a new paradigm for image guidance. Abdom Imaging 2009;34(6):675-685.
35. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24(10):1989-1998.
36. Ducreux M, Baudin E, Schlumberger M. Treatment strategy of neuroendocrine tumors [in French]. Rev Prat 2002;52(3):290-296.
37. Zhao M, Pipe JG, Bonnett J, Evelhoch JL. Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 1996;73(1):61-64.
38. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92(24):2029-2036.
39. Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 2005;30(3):324-341.